Table O.39: Omega-3 versus placebo in children and young people

Quality assessment						Summary of findings					
Participa nts	Risk of	Inconsistenc y	Indirectn ess	Imprecis ion	Publicati on bias	Overall quality of evidence	Study event rates (%)		Relativ e effect	Anticipated absolute effects	
(studies) Follow up	bias						With place bo	With omeg a-3	(95% CI)	Risk with place bo	Risk difference with omega-3 (95% CI)
Targeted behaviour that challenges (severity) – post-treatment (Better indicated by lower values)											
12 (1 study)	seriou s ¹	no serious inconsistenc y	serious ²	very serious ³	undetect ed	⊕⊖⊖ VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	5	7	-		The mean targeted behaviour that challenges (severity) – post-treatment in the intervention groups was 0.37 standard deviations higher (0.79 lower to 1.53 higher)
Adverse events (discontinuation due to adverse events, non-occurrence) – post-treatment											
13	seriou	no serious	serious ²	very	undetect	$\oplus \ominus \ominus \ominus$	5/6	7/7	RR	833	158 more per 1000

Quality assessment						Summary of findings				
(1 study)	S ¹	inconsistenc y	serious ³	ed	VERY LOW ^{1,2,3} due to risk of bias, indirectness, imprecision	(83.3 %)	(100 %)	1.19 (0.78 to 1.83)	per 1000	(from 183 fewer to 692 more)

Crucial limitation for one criterion or some limitations for multiple criteria sufficient to lower ones confidence in the estimate of effect
 Applicability – different populations
 Optimal information size not met; small, single study